Stratec SE (LON: 0RAR)
London
· Delayed Price · Currency is GBP · Price in EUR
35.50
+0.52 (1.48%)
At close: Jan 31, 2025
Stratec SE Revenue
Stratec SE had revenue of 57.23M EUR in the quarter ending September 30, 2024, a decrease of -8.69%. This brings the company's revenue in the last twelve months to 250.54M, down -1.62% year-over-year. In the year 2023, Stratec SE had annual revenue of 261.91M, down -4.63%.
Revenue (ttm)
250.54M EUR
Revenue Growth
-1.62%
P/S Ratio
n/a
Revenue / Employee
169.28K EUR
Employees
1,480
Market Cap
360.85M GBP
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 261.91M | -12.71M | -4.63% |
Dec 31, 2022 | 274.63M | -12.71M | -4.42% |
Dec 31, 2021 | 287.34M | 37.24M | 14.89% |
Dec 31, 2020 | 250.10M | 35.94M | 16.78% |
Dec 31, 2019 | 214.16M | 26.34M | 14.02% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
Hikma Pharmaceuticals | 2.39B |
ConvaTec Group | 1.74B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |